US6310034B1
(en)
|
1993-05-21 |
2001-10-30 |
Ut-Battelle, Llc |
Agouti polypeptide compositions
|
US6471956B1
(en)
|
1994-08-17 |
2002-10-29 |
The Rockefeller University |
Ob polypeptides, modified forms and compositions thereto
|
US6350730B1
(en)
|
1994-08-17 |
2002-02-26 |
The Rockefeller University |
OB polypeptides and modified forms as modulators of body weight
|
US6001968A
(en)
*
|
1994-08-17 |
1999-12-14 |
The Rockefeller University |
OB polypeptides, modified forms and compositions
|
US6429290B1
(en)
|
1994-08-17 |
2002-08-06 |
The Rockefeller University |
OB polypeptides, modified forms and derivatives
|
US5858967A
(en)
*
|
1995-01-20 |
1999-01-12 |
University Of Washington |
Appetite supression factor and related methods
|
US5827734A
(en)
*
|
1995-01-20 |
1998-10-27 |
University Of Washington |
Materials and methods for determining ob protein in a biological sample
|
EP0725078A1
(en)
*
|
1995-01-31 |
1996-08-07 |
Eli Lilly And Company |
Anti-obesity proteins
|
US5580954A
(en)
*
|
1995-01-31 |
1996-12-03 |
Eli Lilly And Company |
Anti-obesity proteins
|
US5563243A
(en)
*
|
1995-01-31 |
1996-10-08 |
Eli Lilly And Company |
Anti-obesity proteins
|
US5605886A
(en)
*
|
1995-01-31 |
1997-02-25 |
Eli Lilly And Company |
Anti-obesity proteins
|
US5567803A
(en)
*
|
1995-01-31 |
1996-10-22 |
Eli Lilly And Company |
Anti-obesity proteins
|
US5552523A
(en)
*
|
1995-01-31 |
1996-09-03 |
Eli Lilly And Company |
Anti-obesity proteins
|
US5554727A
(en)
*
|
1995-01-31 |
1996-09-10 |
Eli Lilly And Company |
Anti-obesity proteins
|
US5574133A
(en)
*
|
1995-01-31 |
1996-11-12 |
Eli Lilly And Company |
Anti-obesity proteins
|
US5567678A
(en)
*
|
1995-01-31 |
1996-10-22 |
Eli Lilly And Company |
Anti-obesity proteins
|
US5552522A
(en)
*
|
1995-01-31 |
1996-09-03 |
Eli Lilly And Company |
Anti-obesity proteins
|
US5594104A
(en)
*
|
1995-01-31 |
1997-01-14 |
Eli Lilly And Company |
Anti-obesity proteins
|
US5559208A
(en)
*
|
1995-01-31 |
1996-09-24 |
Eli Lilly And Company |
Anti-obesity proteins
|
US5569743A
(en)
*
|
1995-01-31 |
1996-10-29 |
Eli Lilly And Company |
Anti-obesity proteins
|
US5563245A
(en)
*
|
1995-01-31 |
1996-10-08 |
Eli Lilly And Company |
Anti-obesity proteins
|
US5563244A
(en)
*
|
1995-01-31 |
1996-10-08 |
Eli Lilly And Company |
Anti-obesity proteins
|
US5691309A
(en)
*
|
1995-01-31 |
1997-11-25 |
Eli Lilly And Company |
Anti-obesity proteins
|
US5594101A
(en)
*
|
1995-03-03 |
1997-01-14 |
Eli Lilly And Company |
Anti-obesity proteins
|
US5719266A
(en)
*
|
1995-03-17 |
1998-02-17 |
Eli Lilly And Company |
Anti-obesity proteins
|
EP0736599A3
(en)
*
|
1995-04-03 |
1996-12-11 |
Takeda Chemical Industries Ltd |
The rat obesity gene, its gene product and its production
|
WO1996031192A1
(de)
*
|
1995-04-07 |
1996-10-10 |
Kuyus-Stiftung |
Kosmetische zusammensetzung zur behandlung von cellulite
|
US5840517A
(en)
*
|
1995-04-26 |
1998-11-24 |
Eli Lilly And Company |
Process for preparing obesity protein analogs
|
US5614379A
(en)
*
|
1995-04-26 |
1997-03-25 |
Eli Lilly And Company |
Process for preparing anti-obesity protein
|
EP0741187A2
(en)
*
|
1995-05-05 |
1996-11-06 |
F. Hoffmann-La Roche Ag |
Recombinant obese (Ob) proteins
|
GB9509164D0
(en)
*
|
1995-05-05 |
1995-06-28 |
Smithkline Beecham Plc |
Novel compounds
|
ZA963530B
(en)
*
|
1995-05-05 |
1996-11-05 |
Hoffmann La Roche |
Recombinant obese (ob) proteins
|
CA2218529A1
(en)
*
|
1995-05-08 |
1996-11-14 |
Chiron Corporation |
Nucleic acids for treating obesity
|
CA2221303A1
(en)
*
|
1995-05-19 |
1996-11-21 |
Dennis Paul Smith |
Obesity gene product
|
US6395509B1
(en)
|
1995-05-26 |
2002-05-28 |
Eli Lilly And Company |
DNA encoding Rhesus ob protein
|
JP2001501906A
(ja)
*
|
1995-05-26 |
2001-02-13 |
イーライ・リリー・アンド・カンパニー |
Rhesus obタンパク質およびdna
|
AU6028396A
(en)
|
1995-06-07 |
1996-12-30 |
Amgen, Inc. |
Ob protein compositions and method
|
GB9511935D0
(en)
*
|
1995-06-13 |
1995-08-09 |
Smithkline Beecham Plc |
Novel compound
|
JPH11508134A
(ja)
*
|
1995-06-22 |
1999-07-21 |
イーライ・リリー・アンド・カンパニー |
肥満症蛋白質中間体およびその製法と使用
|
EP0759441A3
(en)
*
|
1995-06-30 |
1999-06-30 |
Eli Lilly And Company |
Methods of treating neuropeptide Y-associated conditions
|
ZA965346B
(en)
*
|
1995-06-30 |
1997-12-24 |
Lilly Co Eli |
Methods of treating neuropeptide Y-associated conditions.
|
IL122718A0
(en)
*
|
1995-06-30 |
1998-08-16 |
Lilly Co Eli |
Methods for treating diabetes
|
JP4173913B2
(ja)
*
|
1995-08-17 |
2008-10-29 |
アムジエン・インコーポレーテツド |
Obタンパク質組成物を用いて血中脂質レベルを減少させ又は減少した血中脂質レベルを維持する方法
|
AU7072896A
(en)
*
|
1995-09-19 |
1997-04-09 |
Eli Lilly And Company |
Dna encoding medicinal proteins
|
WO1997016550A1
(en)
*
|
1995-11-02 |
1997-05-09 |
Bristol-Myers Squibb Company |
Polypeptide fragments derived from the obese gene product
|
CA2358862A1
(en)
*
|
1995-11-22 |
1997-05-29 |
Amgen Inc. |
Methods of increasing lean tissue mass using ob protein compositions
|
US6936439B2
(en)
|
1995-11-22 |
2005-08-30 |
Amgen Inc. |
OB fusion protein compositions and methods
|
US20030040467A1
(en)
|
1998-06-15 |
2003-02-27 |
Mary Ann Pelleymounter |
Ig/ob fusions and uses thereof.
|
US6225446B1
(en)
|
1995-12-06 |
2001-05-01 |
Schering Corporation |
Mutational variants of mammalian proteins
|
AU1406497A
(en)
*
|
1995-12-06 |
1997-06-27 |
Schering Corporation |
Mutational variants of mammalian ob gene proteins
|
US7632922B1
(en)
|
1995-12-22 |
2009-12-15 |
Amgen, Inc. |
Osteoprotegerin
|
US6369027B1
(en)
*
|
1995-12-22 |
2002-04-09 |
Amgen Inc. |
Osteoprotegerin
|
US6620413B1
(en)
|
1995-12-27 |
2003-09-16 |
Genentech, Inc. |
OB protein-polymer chimeras
|
CA2238307A1
(en)
*
|
1995-12-27 |
1997-07-10 |
Genentech, Inc. |
Ob protein derivatives having prolonged half-life
|
US7074397B1
(en)
|
1996-01-08 |
2006-07-11 |
Genentech, Inc. |
Method for enhancing proliferation or differentiation of a cell using ob protein
|
US6541604B1
(en)
|
1996-01-08 |
2003-04-01 |
Genentech, Inc. |
Leptin receptor having a WSX motif
|
US20050019325A1
(en)
|
1996-01-08 |
2005-01-27 |
Carter Paul J. |
WSX receptor agonist antibodies
|
US6087129A
(en)
|
1996-01-19 |
2000-07-11 |
Betagene, Inc. |
Recombinant expression of proteins from secretory cell lines
|
US6110707A
(en)
*
|
1996-01-19 |
2000-08-29 |
Board Of Regents, The University Of Texas System |
Recombinant expression of proteins from secretory cell lines
|
AU2246097A
(en)
*
|
1996-01-25 |
1997-08-20 |
Eli Lilly And Company |
Obesity protein analog compounds and formulations thereof
|
CA2247503A1
(en)
*
|
1996-03-01 |
1997-09-04 |
Amgen Inc. |
Canine ob protein compositions and methods
|
CA2250570A1
(en)
*
|
1996-03-26 |
1997-10-02 |
Eli Lilly And Company |
Formulations of ob protein
|
CA2251808A1
(en)
*
|
1996-04-19 |
1997-10-30 |
Zymogenetics, Inc. |
Methods for inducing bone formation
|
US6007998A
(en)
*
|
1996-04-22 |
1999-12-28 |
Merck & Co., Inc. |
Leptin assay
|
US6025324A
(en)
*
|
1996-05-15 |
2000-02-15 |
Hoffmann-La Roche Inc. |
Pegylated obese (ob) protein compositions
|
ATE368471T1
(de)
*
|
1996-06-04 |
2007-08-15 |
Scripps Research Inst |
Diagnostische und therapeutische verfahren in zusammenhang mit der regulation der energiemobilisation durch ob-protein und ob- antikörper
|
CA2257240A1
(en)
*
|
1996-06-06 |
1997-12-11 |
Smithkline Beecham P.L.C. |
Fragments of leptin (ob protein)
|
WO1997048419A1
(en)
*
|
1996-06-20 |
1997-12-24 |
Merck & Co., Inc. |
Gene therapy for obesity
|
US6630346B1
(en)
*
|
1996-06-20 |
2003-10-07 |
Merck & Co., Inc. |
Gene therapy for obesity
|
JP2002514904A
(ja)
*
|
1996-06-20 |
2002-05-21 |
メルク エンド カンパニー インコーポレーテッド |
肥満に対する遺伝子治療
|
US6001816A
(en)
*
|
1996-06-20 |
1999-12-14 |
Merck & Co., Inc. |
Gene therapy for leptin deficiency
|
US5869037A
(en)
*
|
1996-06-26 |
1999-02-09 |
Cornell Research Foundation, Inc. |
Adenoviral-mediated gene transfer to adipocytes
|
US20020110857A1
(en)
*
|
1996-07-31 |
2002-08-15 |
Spurlock Michael E. |
Bovine leptin protein, antisense and antibody
|
US6277592B1
(en)
|
1996-07-31 |
2001-08-21 |
Purina Mills, Inc. |
Porcine leptin protein, nucleic acid sequences coding therefor and uses thereof
|
AU4237797A
(en)
*
|
1996-08-30 |
1998-03-19 |
Amgen, Inc. |
Methods of increasing sensitivity of an individual to OB protein by upregula ting OB protein receptor
|
HUP9904023A3
(en)
|
1996-09-20 |
2002-01-28 |
Hoechst Ag |
Use of leptin antagonists for treating insulin resistance in type ii diabetes
|
SE520392C2
(sv)
|
1996-09-27 |
2003-07-01 |
Creative Peptides Sweden Ab C |
Specifika peptider för behandling av diabetes mellitus
|
WO1998016545A1
(en)
*
|
1996-10-11 |
1998-04-23 |
Eli Lilly And Company |
Therapeutic proteins
|
UA65549C2
(uk)
|
1996-11-05 |
2004-04-15 |
Елі Ліллі Енд Компані |
Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
|
NL1004559C2
(nl)
*
|
1996-11-18 |
1998-05-19 |
Unilife |
Boter.
|
AU5654998A
(en)
*
|
1996-12-06 |
1998-06-29 |
F. Hoffmann-La Roche Ag |
Muteins of obese protein
|
EP1835030A1
(en)
*
|
1996-12-20 |
2007-09-19 |
Amgen, Inc. |
OB fusion protein compositions and methods
|
CA2274799A1
(en)
*
|
1996-12-20 |
1998-07-02 |
Eli Lilly And Company |
Anti-obesity proteins
|
CA2217698A1
(en)
*
|
1996-12-20 |
1998-06-20 |
Eli Lilly And Company |
Anti-obesity proteins
|
SG120054A1
(en)
*
|
1997-04-15 |
2006-03-28 |
Csir |
Appetite suppressant steroidal glycosides
|
US20020019352A1
(en)
*
|
1997-04-17 |
2002-02-14 |
David N. Brems |
Stable, active, human ob protein compositions and methods
|
AU2951797A
(en)
*
|
1997-06-06 |
1998-12-21 |
Smithkline Beecham Plc |
Use of leptin antagonists for the treatment of diabetes
|
US6017876A
(en)
|
1997-08-15 |
2000-01-25 |
Amgen Inc. |
Chemical modification of granulocyte-colony stimulating factor (G-CSF) bioactivity
|
CA2312188C
(en)
|
1997-12-08 |
2010-06-29 |
Lexigen Pharmaceuticals Corp. |
Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
|
US5866547A
(en)
*
|
1998-01-20 |
1999-02-02 |
Beth Israel Deaconess Medical Center |
Methods of neuroendocrine regulation of affective disorders
|
EP0950417A3
(en)
|
1998-02-23 |
2000-02-23 |
Pfizer Products Inc. |
Treatment of skeletal disorders
|
US6541033B1
(en)
|
1998-06-30 |
2003-04-01 |
Amgen Inc. |
Thermosensitive biodegradable hydrogels for sustained delivery of leptin
|
US6210924B1
(en)
|
1998-08-11 |
2001-04-03 |
Amgen Inc. |
Overexpressing cyclin D 1 in a eukaryotic cell line
|
EP0996727B1
(en)
*
|
1998-08-12 |
2003-01-08 |
Medical Research Council |
Gene conferring obese phenotype
|
US6777388B1
(en)
*
|
1998-08-21 |
2004-08-17 |
Clf Medical Technology Acceleration Program, Inc. |
Leptin-related peptides
|
US7208572B2
(en)
|
1998-08-21 |
2007-04-24 |
Albany Medical College |
Leptin-related peptides
|
US7056504B1
(en)
|
1998-08-27 |
2006-06-06 |
Massachusetts Institute Of Technology |
Rationally designed heparinases derived from heparinase I and II
|
WO2000012726A2
(en)
*
|
1998-08-27 |
2000-03-09 |
Massachusetts Institute Of Technology |
Rationally designed heparinases derived from heparinase i and ii
|
US6420339B1
(en)
|
1998-10-14 |
2002-07-16 |
Amgen Inc. |
Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
|
US6660843B1
(en)
|
1998-10-23 |
2003-12-09 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
AU773891C
(en)
|
1998-10-23 |
2005-02-17 |
Kirin-Amgen Inc. |
Dimeric thrombopoietin peptide mimetics binding to MP1 receptor and having thrombopoietic activity
|
US7488590B2
(en)
|
1998-10-23 |
2009-02-10 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
US6245740B1
(en)
|
1998-12-23 |
2001-06-12 |
Amgen Inc. |
Polyol:oil suspensions for the sustained release of proteins
|
JP2002533124A
(ja)
|
1998-12-31 |
2002-10-08 |
カイロン コーポレイション |
Hivポリペプチドの改善された発現およびウイルス様粒子の生成
|
AU778939B2
(en)
*
|
1999-01-07 |
2004-12-23 |
Emd Lexigen Research Center Corp. |
Expression and export of anti-obesity proteins as Fc fusion proteins
|
WO2000047741A1
(en)
*
|
1999-02-12 |
2000-08-17 |
Amgen Inc. |
Glycosylated leptin compositions and related methods
|
WO2000056903A2
(en)
*
|
1999-03-22 |
2000-09-28 |
Zymogenetics, Inc. |
IMPROVED METHODS FOR PRODUCING PROTEINS IN TRANSFORMED $i(PICHIA)
|
US20050272652A1
(en)
|
1999-03-29 |
2005-12-08 |
Gault Victor A |
Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
|
US6597996B1
(en)
*
|
1999-04-23 |
2003-07-22 |
Massachusetts Institute Of Technology |
Method for indentifying or characterizing properties of polymeric units
|
SK782002A3
(en)
|
1999-07-21 |
2003-08-05 |
Lexigen Pharm Corp |
FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
US8106098B2
(en)
|
1999-08-09 |
2012-01-31 |
The General Hospital Corporation |
Protein conjugates with a water-soluble biocompatible, biodegradable polymer
|
DK1200479T3
(da)
|
1999-08-09 |
2006-05-15 |
Emd Lexigen Res Ct Corp |
Multiple cytokin-antistof-komplekser
|
GB2355657B
(en)
*
|
1999-10-27 |
2004-07-28 |
Phytopharm Plc |
Inhibitors Of Gastric Acid Secretion
|
WO2001058957A2
(en)
|
2000-02-11 |
2001-08-16 |
Lexigen Pharmaceuticals Corp. |
Enhancing the circulating half-life of antibody-based fusion proteins
|
ES2527853T3
(es)
*
|
2000-03-08 |
2015-01-30 |
Massachusetts Institute Of Technology |
Heparinasa III y sus usos
|
DE60117781T2
(de)
|
2000-04-21 |
2006-11-23 |
Amgen Inc., Thousand Oaks |
Peptidderivate des apolipoproteins-a1/aii
|
US6677136B2
(en)
|
2000-05-03 |
2004-01-13 |
Amgen Inc. |
Glucagon antagonists
|
GB2363985B
(en)
*
|
2000-06-30 |
2004-09-29 |
Phytopharm Plc |
Extracts,compounds & pharmaceutical compositions having anti-diabetic activity and their use
|
US6443013B1
(en)
*
|
2000-08-04 |
2002-09-03 |
Samsung Electronics Co., Ltd. |
Rotary test fixture
|
EP1319183B1
(en)
|
2000-09-12 |
2009-03-25 |
Massachusetts Institute Of Technology |
Methods and products related to low molecular weight heparin
|
EP1328260A2
(en)
|
2000-10-18 |
2003-07-23 |
Massachusetts Institute Of Technology |
Methods and products related to pulmonary delivery of polysaccharides
|
US7054758B2
(en)
|
2001-01-30 |
2006-05-30 |
Sciona Limited |
Computer-assisted means for assessing lifestyle risk factors
|
CA2438652A1
(en)
|
2001-02-19 |
2002-09-06 |
Merck Patent Gesellschaft Mit Beschraenkter Haftung |
Method for identification of t-cell epitopes and use for preparing molecules with reeduced immunogenicity
|
KR100900176B1
(ko)
|
2001-03-07 |
2009-06-02 |
메르크 파텐트 게엠베하 |
하이브리드 이소타입 항체 부분구조를 포함하는 단백질을위한 발현 기술
|
US6992174B2
(en)
|
2001-03-30 |
2006-01-31 |
Emd Lexigen Research Center Corp. |
Reducing the immunogenicity of fusion proteins
|
CA2446087C
(en)
|
2001-05-03 |
2013-06-18 |
Stephen D. Gillies |
Recombinant tumor specific antibody and use thereof
|
EA010435B1
(ru)
|
2001-05-11 |
2008-08-29 |
Амген, Инк. |
Связывающиеся с tall-1 молекулы и их применение
|
US20030083286A1
(en)
*
|
2001-08-22 |
2003-05-01 |
Ching-Leou Teng |
Bioadhesive compositions and methods for enhanced intestinal drug absorption
|
US20030124196A1
(en)
*
|
2001-08-22 |
2003-07-03 |
Susan Weinbach |
Pulsatile release compositions and methods for enhanced intestinal drug absorption
|
DE10145553B4
(de)
*
|
2001-09-16 |
2006-06-08 |
Gene Architects Ag |
Nukleinsäure für einen Klonierungsvektor
|
US9969980B2
(en)
|
2001-09-21 |
2018-05-15 |
Garnet Biotherapeutics |
Cell populations which co-express CD49c and CD90
|
US7138370B2
(en)
|
2001-10-11 |
2006-11-21 |
Amgen Inc. |
Specific binding agents of human angiopoietin-2
|
PT2219031E
(pt)
*
|
2001-10-22 |
2013-05-17 |
Amgen Inc |
Uso de leptina para tratamento de lipoatrofia humana e método para determinar predisposição ao referido tratamento
|
WO2003039454A2
(en)
|
2001-10-23 |
2003-05-15 |
Oklahoma Medical Research Foundation |
Beta-secretase inhibitors and methods of use
|
AU2002357784B2
(en)
|
2001-12-04 |
2008-07-31 |
Merck Patent Gmbh |
Immunocytokines with modulated selectivity
|
ATE410459T1
(de)
|
2002-01-14 |
2008-10-15 |
Gen Hospital Corp |
Bioabbaubare polyketale, verfahren zu ihrer herstellung sowie ihre verwendung
|
US20030191056A1
(en)
|
2002-04-04 |
2003-10-09 |
Kenneth Walker |
Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
|
CA2387003A1
(en)
*
|
2002-05-21 |
2003-11-21 |
984012 Alberta Ltd. |
Method for improving efficiencies in livestock production
|
AU2003256613A1
(en)
|
2002-07-19 |
2004-02-09 |
Amgen Inc. |
Protein conjugates with a water-soluble biocompatible, biogradable polymer
|
US8030459B2
(en)
|
2002-07-19 |
2011-10-04 |
The General Hospital Corporation |
Oxime conjugates and methods for their formation and use
|
WO2004019866A2
(en)
|
2002-08-28 |
2004-03-11 |
Immunex Corporation |
Compositions and methods for treating cardiovascular disease
|
JP4494977B2
(ja)
|
2002-12-17 |
2010-06-30 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Gd2に結合するマウス14.18抗体のヒト化抗体(h14.18)およびそのil−2融合タンパク質
|
US9592258B2
(en)
|
2003-06-27 |
2017-03-14 |
DePuy Synthes Products, Inc. |
Treatment of neurological injury by administration of human umbilical cord tissue-derived cells
|
US7875272B2
(en)
|
2003-06-27 |
2011-01-25 |
Ethicon, Incorporated |
Treatment of stroke and other acute neuraldegenerative disorders using postpartum derived cells
|
PL1641914T3
(pl)
|
2003-06-27 |
2017-01-31 |
DePuy Synthes Products, Inc. |
Komórki pochodzące z poporodowej tkanki łożyska oraz sposoby uzyskiwania i zastosowania tych komórek
|
US8491883B2
(en)
|
2003-06-27 |
2013-07-23 |
Advanced Technologies And Regenerative Medicine, Llc |
Treatment of amyotrophic lateral sclerosis using umbilical derived cells
|
US9572840B2
(en)
|
2003-06-27 |
2017-02-21 |
DePuy Synthes Products, Inc. |
Regeneration and repair of neural tissue using postpartum-derived cells
|
US8790637B2
(en)
|
2003-06-27 |
2014-07-29 |
DePuy Synthes Products, LLC |
Repair and regeneration of ocular tissue using postpartum-derived cells
|
ATE554108T1
(de)
|
2003-07-25 |
2012-05-15 |
Amgen Inc |
Verfahren bezüglich ldcam und crtam
|
JP4585186B2
(ja)
*
|
2003-07-31 |
2010-11-24 |
杏林製薬株式会社 |
肥満、糖尿病及び脂質代謝異常の新規な予防又は治療剤
|
EP1667726B1
(en)
|
2003-09-05 |
2011-05-04 |
The General Hospital Corporation |
Polyacetal drug conjugates as release system
|
CA2543322A1
(en)
|
2003-10-21 |
2005-05-12 |
Sention, Inc. |
Carbamoyl esters that inhibit cholinesterase and release pharmacologically active agents
|
DE10352510A1
(de)
*
|
2003-11-07 |
2005-06-23 |
Forschungsinstitut Für Die Biologie Landwirtschaftlicher Nutztiere |
Verfahren zur Identifizierung von Wirkstoffen zur Beeinflussung der Körpermasse und des Fettansatzes
|
AU2004313245B2
(en)
|
2003-12-30 |
2011-04-14 |
Durect Corporation |
Polymeric implants, preferably containing a mixture of PEG and PLG, for controlled release of active agents, preferably a GNRH
|
KR20120034237A
(ko)
|
2004-02-11 |
2012-04-10 |
아밀린 파마슈티칼스, 인크. |
선택가능한 특성을 갖는 하이브리드 폴리펩티드
|
US8076288B2
(en)
|
2004-02-11 |
2011-12-13 |
Amylin Pharmaceuticals, Inc. |
Hybrid polypeptides having glucose lowering activity
|
WO2006010057A2
(en)
|
2004-07-08 |
2006-01-26 |
Amgen Inc. |
Therapeutic peptides
|
WO2006014798A2
(en)
*
|
2004-07-27 |
2006-02-09 |
Mount Sinai School Of Medicine |
Methods and compositions for using sax2
|
AU2005286774A1
(en)
|
2004-09-17 |
2006-03-30 |
Comentis, Inc |
Amino-containing compounds which inhibit memapsin 2 beta-secretase activity and methods of use thereof
|
CA2581237C
(en)
|
2004-09-24 |
2018-11-06 |
Angioblast Systems, Inc. |
Method of enhancing proliferation and/or survival of mesenchymal precursor cells (mpc)
|
CN102391981B
(zh)
|
2004-09-24 |
2014-08-20 |
麦索布莱斯特公司 |
多能扩增间充质前体细胞子代(memp)及其应用
|
EP2286838A3
(en)
|
2004-11-01 |
2013-09-04 |
Amylin Pharmaceuticals, LLC |
Treatment of obesity and related disorders
|
US8394765B2
(en)
|
2004-11-01 |
2013-03-12 |
Amylin Pharmaceuticals Llc |
Methods of treating obesity with two different anti-obesity agents
|
CA2585549A1
(en)
|
2004-11-18 |
2006-05-26 |
Vib Vzw |
Novel type leptin receptor antagonist
|
US7307142B2
(en)
*
|
2004-11-26 |
2007-12-11 |
Yissum Research And Development Company Of The Hebrew University Of Jerusalem |
Leptin antagonists
|
CA2592435C
(en)
|
2004-12-23 |
2017-03-28 |
Ethicon, Incorporated |
Treatment of stroke and other acute neural degenerative disorders using postpartum derived cells
|
BRPI0606992A2
(pt)
|
2005-02-11 |
2009-07-28 |
Amylin Pharmaceuticals Inc |
análogo e polipeptìdeos hìbridos de gip com propriedades selecionáveis
|
US8263545B2
(en)
|
2005-02-11 |
2012-09-11 |
Amylin Pharmaceuticals, Inc. |
GIP analog and hybrid polypeptides with selectable properties
|
KR20080015079A
(ko)
|
2005-04-08 |
2008-02-18 |
코멘티스, 인코포레이티드 |
베타 세크레타제 활성을 억제하는 화합물 및 이것의 사용방법
|
US8367405B2
(en)
|
2005-04-12 |
2013-02-05 |
Mesoblast, Inc. |
Isolation of adult multipotential cells by tissue non-specific alkaline phosphatase
|
US7833979B2
(en)
|
2005-04-22 |
2010-11-16 |
Amgen Inc. |
Toxin peptide therapeutic agents
|
BRPI0614649A2
(pt)
|
2005-08-11 |
2011-04-12 |
Amylin Pharmaceuticals Inc |
polipeptìdeos hìbridos com propriedades selecionáveis
|
EP2330124B1
(en)
|
2005-08-11 |
2015-02-25 |
Amylin Pharmaceuticals, LLC |
Hybrid polypeptides with selectable properties
|
US8008453B2
(en)
|
2005-08-12 |
2011-08-30 |
Amgen Inc. |
Modified Fc molecules
|
US8227408B2
(en)
*
|
2005-09-07 |
2012-07-24 |
Neurotez, Inc. |
Leptin as an anti-amyloidogenic biologic and methods for delaying the onset and reducing Alzheimer's disease-like pathology
|
AU2006344395B2
(en)
|
2005-10-13 |
2013-05-02 |
Human Genome Sciences, Inc. |
Methods and compositions for use in treatment of patients with autoantibody positive diseases
|
AR056806A1
(es)
|
2005-11-14 |
2007-10-24 |
Amgen Inc |
Moleculas quimericas de anticuerpo rankl- pth/ pthrp
|
CN101374946B
(zh)
|
2005-12-16 |
2017-07-18 |
伊西康公司 |
用于在组织相容性不匹配的移植中抑制有害的免疫反应的组合物和方法
|
US9125906B2
(en)
|
2005-12-28 |
2015-09-08 |
DePuy Synthes Products, Inc. |
Treatment of peripheral vascular disease using umbilical cord tissue-derived cells
|
WO2007103322A2
(en)
|
2006-03-07 |
2007-09-13 |
Vaxinnate Corporation |
Compositions that include hemagglutinin, methods of making and methods of use thereof
|
US9283260B2
(en)
|
2006-04-21 |
2016-03-15 |
Amgen Inc. |
Lyophilized therapeutic peptibody formulations
|
MX2008014744A
(es)
|
2006-05-19 |
2009-02-10 |
Glycofi Inc |
Composiciones de eritrocpoyetina.
|
CA2787343C
(en)
|
2006-06-26 |
2016-08-02 |
Amgen Inc. |
Compositions comprising modified lcat and uses thereof
|
US8778977B2
(en)
|
2006-06-30 |
2014-07-15 |
Sunesis Pharmaceuticals, Inc. |
Pyridinonyl PDK1 inhibitors
|
US8497240B2
(en)
|
2006-08-17 |
2013-07-30 |
Amylin Pharmaceuticals, Llc |
DPP-IV resistant GIP hybrid polypeptides with selectable properties
|
PE20081140A1
(es)
|
2006-10-25 |
2008-09-22 |
Amgen Inc |
Agentes terapeuticos a base de peptidos derivados de toxinas
|
EP2578216A1
(en)
|
2006-11-22 |
2013-04-10 |
Seaside Therapeutics, Inc. |
Methods of treating fragile x syndrome
|
CA2687141C
(en)
|
2007-05-22 |
2014-04-01 |
Amgen Inc. |
Compositions and methods for producing bioactive fusion proteins
|
CA2691531C
(en)
|
2007-06-22 |
2016-11-01 |
Board Of Regents,The University Of Texas System |
Formation of stable submicron peptide or protein particles by thin film freezing
|
DK2489731T3
(en)
|
2007-07-26 |
2014-11-17 |
Amgen Inc |
Modified lecithin-cholesterol acyltransferase enzymes
|
CN101868457B
(zh)
|
2007-09-24 |
2013-02-13 |
科门蒂斯公司 |
作为β-分泌酶抑制剂用于治疗的(3-羟基-4-氨基-丁-2-基)-3-(2-噻唑-2-基-吡咯烷-1-羰基)苯甲酰胺衍生物和相关化合物
|
JP2011519828A
(ja)
|
2008-04-18 |
2011-07-14 |
バクシネート コーポレーション |
フラジェリンの欠失変異体と使用方法
|
AU2009248914A1
(en)
*
|
2008-05-21 |
2009-11-26 |
Neurotez, Inc. |
Methods for Treating Neurodegenerative Disorders Related to Neurofibrillary Tangles
|
CN102105146A
(zh)
|
2008-05-23 |
2011-06-22 |
国立犹太保健医院 |
用于治疗与暴露于烷化物质有关的损伤的方法
|
US8501686B2
(en)
|
2008-06-05 |
2013-08-06 |
University Of Michigan |
Method of treating fatty liver diseases and conditions in non-lipodystrophic subjects
|
WO2009158432A2
(en)
|
2008-06-27 |
2009-12-30 |
Amgen Inc. |
Ang-2 inhibition to treat multiple sclerosis
|
JP6144873B2
(ja)
|
2008-09-15 |
2017-06-07 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
Ire1、src、及びabl活性を調節するための方法及び組成物
|
NZ592113A
(en)
|
2008-10-15 |
2012-04-27 |
Intarcia Therapeutics Inc |
Highly concentrated drug particles, formulations, suspensions and uses thereof
|
EP2349341B1
(en)
|
2008-10-15 |
2013-10-09 |
Baxter Healthcare SA |
Pegylation of recombinant blood coagulation factors in the presence of bound antibodies
|
CA2742600A1
(en)
*
|
2008-11-04 |
2010-05-14 |
Nikolaos Tezapsidis |
Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amlyoid beta
|
AR074584A1
(es)
|
2008-12-10 |
2011-01-26 |
Mersana Therapeutics Inc |
Formulaciones farmaceuticas de conjugados camtotecina-polimero biocompatibles biodegradables
|
US10179900B2
(en)
|
2008-12-19 |
2019-01-15 |
DePuy Synthes Products, Inc. |
Conditioned media and methods of making a conditioned media
|
SI2379087T1
(sl)
|
2008-12-19 |
2015-01-30 |
DePuy Synthes Products, LLC |
Celice, izpeljane iz popkovniäśnega tkiva, za zdravljenje nevropatske boleäśine in spastiäśnosti
|
ES2665883T3
(es)
|
2008-12-19 |
2018-04-30 |
DePuy Synthes Products, Inc. |
Tratamiento de enfermedades y trastornos pulmonares y pulmonares
|
MX362028B
(es)
|
2009-02-03 |
2019-01-04 |
Amunix Pharmaceuticals Inc |
Polipeptidos recombinantes extendidos y composiciones que comprenden los mismos.
|
EP2411504B1
(en)
|
2009-03-26 |
2017-05-10 |
DePuy Synthes Products, Inc. |
Human umbilical cord tissue cells as therapy for alzheimer's disease
|
JP2012523434A
(ja)
|
2009-04-10 |
2012-10-04 |
アミリン・ファーマシューティカルズ,インコーポレイテッド |
エストロゲン欠乏哺乳類のためのアミリンアゴニスト化合物
|
AU2010262974A1
(en)
|
2009-06-19 |
2012-02-02 |
Medimmune, Llc |
Protease variants
|
AU2010284255B2
(en)
|
2009-08-17 |
2016-11-17 |
Memorial Sloan-Kettering Cancer Center |
Heat shock protein binding compounds, compositions, and methods for making and using same
|
US9029359B2
(en)
|
2009-09-04 |
2015-05-12 |
Biogen Idec Ma, Inc. |
Heteroaryl Btk inhibitors
|
CN107011330B
(zh)
|
2009-09-04 |
2020-07-03 |
比奥根Ma公司 |
布鲁顿酪氨酸激酶抑制剂
|
RU2017109664A
(ru)
|
2009-10-06 |
2019-01-23 |
Милленниум Фармасьютикалз, Инк. |
Гетероциклические соединения, используемые в качестве ингибиторов pdk1
|
CA2780205A1
(en)
|
2009-11-05 |
2011-05-12 |
Brown University |
Methods of treating elevations in mtor signaling
|
US20110136728A1
(en)
*
|
2009-12-09 |
2011-06-09 |
Patricia Grasso |
Methods of increasing bone formation using leptin-related peptides
|
KR102079160B1
(ko)
|
2009-12-10 |
2020-02-19 |
더 리젠츠 오브 더 유니버시티 오브 캘리포니아 |
아밀로이드 결합제
|
WO2011126903A2
(en)
|
2010-03-30 |
2011-10-13 |
Verseon, Inc. |
Multisubstituted aromatic compounds as inhibitors of thrombin
|
CN101812450B
(zh)
*
|
2010-04-28 |
2012-01-11 |
中国农业大学 |
辅助鉴定具有不同体重性状鸡的方法及其专用引物
|
CA2813038C
(en)
|
2010-09-28 |
2021-12-28 |
Amylin Pharmaceuticals, Llc |
Highly soluble leptins
|
US9273028B2
(en)
|
2010-10-29 |
2016-03-01 |
Biogen Ma Inc. |
Heterocyclic tyrosine kinase inhibitors
|
WO2012112451A1
(en)
|
2011-02-14 |
2012-08-23 |
Allergan, Inc. |
Ester derivatives of bimatoprost compositions and methods
|
DK2710007T3
(da)
|
2011-05-17 |
2020-01-27 |
Principia Biopharma Inc |
Kinasehæmmere
|
EP2714069A4
(en)
|
2011-05-25 |
2015-06-24 |
Amylin Pharmaceuticals Llc |
LONG-TERM CONJUGATES WITH TWO HORMONES
|
EP2721155A4
(en)
*
|
2011-06-15 |
2014-12-31 |
Nse Products Inc |
IDENTIFICATION OF CALORIC RESTRICTION AND MIMETIC RESTRICTION MARKERS
|
JP6040464B2
(ja)
|
2011-07-08 |
2016-12-07 |
アエゲリオン・ファーマシューティカルズ・インコーポレイテッドAegerion Pharmaceuticals, Inc. |
作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド
|
JP5937210B2
(ja)
|
2011-08-10 |
2016-06-22 |
デピュイ・シンセス・プロダクツ・インコーポレイテッド |
臍帯組織由来細胞を用いた末梢血管疾患の治療
|
MX370814B
(es)
|
2011-09-02 |
2020-01-08 |
Univ California |
Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas.
|
CA2853729A1
(en)
|
2011-10-28 |
2013-05-02 |
Board Of Regents, The University Of Texas System |
Novel compositions and methods for treating cancer
|
EP2794854B1
(en)
|
2011-12-23 |
2018-06-20 |
DePuy Synthes Products, Inc. |
Detection of human umbilical cord tissue-derived cells
|
JP6399660B2
(ja)
|
2012-04-10 |
2018-10-03 |
ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア |
癌治療用組成物および方法
|
AR091273A1
(es)
|
2012-06-08 |
2015-01-21 |
Biogen Idec Inc |
Inhibidores de pirimidinil tirosina quinasa
|
US9353087B2
(en)
|
2012-06-08 |
2016-05-31 |
Biogen Ma Inc. |
Inhibitors of Bruton's tyrosine kinase
|
WO2013188452A1
(en)
|
2012-06-11 |
2013-12-19 |
The Regents Of The University Of California |
Compounds and methods of treating cancer
|
US9024042B2
(en)
|
2012-08-27 |
2015-05-05 |
Allergan, Inc. |
Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes
|
US9090595B2
(en)
|
2012-08-27 |
2015-07-28 |
Allergan, Inc. |
Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes
|
US8932598B2
(en)
|
2012-08-28 |
2015-01-13 |
Vaxinnate Corporation |
Fusion proteins and methods of use
|
BR112015006828A8
(pt)
|
2012-09-26 |
2019-09-17 |
Univ California |
composto, ou um sal farmaceuticamente aceitável do mesmo; composição farmacêutica; uso do composto; e método para modular a atividade de uma proteína ire1
|
HUE040496T2
(hu)
|
2012-09-27 |
2019-03-28 |
Childrens Medical Ct Corp |
Vegyületek elhízás kezelésére és alkalmazási eljárásaik
|
US9364462B2
(en)
|
2012-10-30 |
2016-06-14 |
The Regents Of The University Of California |
Alpha-1-adrenergic receptor agonist therapy
|
AU2013204922B2
(en)
|
2012-12-20 |
2015-05-14 |
Celgene Corporation |
Chimeric antigen receptors
|
NZ750426A
(en)
|
2013-02-06 |
2020-06-26 |
Celgene Corp |
Modified t lymphocytes having improved specificity
|
AU2014236356A1
(en)
|
2013-03-14 |
2015-09-24 |
The Regents Of The University Of California |
Thiosaccharide mucolytic agents
|
CA2901529A1
(en)
|
2013-03-15 |
2014-09-18 |
Allergan, Inc. |
Bimatoprost for enhancement of leptin production
|
CN105246902B
(zh)
|
2013-03-15 |
2018-05-04 |
加利福尼亚大学董事会 |
无环核苷膦酸二酯
|
US9227978B2
(en)
|
2013-03-15 |
2016-01-05 |
Araxes Pharma Llc |
Covalent inhibitors of Kras G12C
|
NZ711064A
(en)
|
2013-03-15 |
2019-06-28 |
Verseon Corp |
Pyridone-substituted pyrazolyl compounds as serine protease inhibitors
|
WO2014152177A1
(en)
|
2013-03-15 |
2014-09-25 |
Anthrogenesis Corporation |
Modified t lymphocytes
|
CN110423221A
(zh)
|
2013-03-15 |
2019-11-08 |
维颂公司 |
作为凝血酶抑制剂的卤代吡唑
|
CA2917527C
(en)
|
2013-07-15 |
2022-06-14 |
Board Of Regents, The University Of Texas System |
Compounds and methods for treating cancer, neurological disorders, ethanol withdrawal, anxiety, depression, and neuropathic pain
|
WO2015026849A1
(en)
|
2013-08-19 |
2015-02-26 |
The Regents Of The University Of California |
Compounds and methods for treating an epileptic disorder
|
WO2015031799A1
(en)
|
2013-08-30 |
2015-03-05 |
The Regents Of The University Of California, A California Corporation |
Scintillator nanocrystal-containing compositions and methods for their use
|
TWI659021B
(zh)
|
2013-10-10 |
2019-05-11 |
亞瑞克西斯製藥公司 |
Kras g12c之抑制劑
|
RS58422B1
(sr)
|
2013-11-26 |
2019-04-30 |
Childrens Medical Ct Corp |
Jedinjenja za tretiranje gojaznosti i postupci za njihovu upotrebu
|
CA2932608C
(en)
|
2013-12-11 |
2023-02-14 |
Biogen Ma Inc. |
Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
|
ES2713196T3
(es)
|
2013-12-11 |
2019-05-20 |
Biogen Ma Inc |
Compuestos de biarilo útiles para el tratamiento de enfermedades humanas en oncología, neurología e inmunología
|
JP6491214B2
(ja)
|
2013-12-23 |
2019-03-27 |
メモリアル スローン ケタリング キャンサー センター |
放射性標識のための方法および試薬
|
AU2015259752B2
(en)
|
2014-02-20 |
2019-06-20 |
Allergan, Inc. |
Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes
|
US20170209408A1
(en)
|
2014-04-03 |
2017-07-27 |
The Children's Medical Center Corporation |
Hsp90 inhibitors for the treatment of obesity and methods of use thereof
|
WO2015175707A1
(en)
|
2014-05-13 |
2015-11-19 |
Memorial Sloan Kettering Cancer Center |
Hsp70 modulators and methods for making and using the same
|
WO2016004383A1
(en)
|
2014-07-03 |
2016-01-07 |
City Of Hope |
Tumor-selective ctla-4 antagonists
|
CN106795497A
(zh)
|
2014-08-12 |
2017-05-31 |
人类起源公司 |
被工程化以归巢至淋巴结b细胞区、皮肤或胃肠道的car‑t淋巴细胞
|
KR102589658B1
(ko)
|
2014-09-15 |
2023-10-13 |
더 리젠츠 오브 더 유니버시티 오브 캘리포니아 |
뉴클레오타이드 유사체
|
WO2016044662A1
(en)
|
2014-09-17 |
2016-03-24 |
Verseon Corporation |
Pyrazolyl-substituted pyridone compounds as serine protease inhibitors
|
JO3556B1
(ar)
|
2014-09-18 |
2020-07-05 |
Araxes Pharma Llc |
علاجات مدمجة لمعالجة السرطان
|
WO2016049568A1
(en)
|
2014-09-25 |
2016-03-31 |
Araxes Pharma Llc |
Methods and compositions for inhibition of ras
|
JP2017528498A
(ja)
|
2014-09-25 |
2017-09-28 |
アラクセス ファーマ エルエルシー |
Kras g12c変異体タンパク質のインヒビター
|
EP3201192B1
(en)
|
2014-10-02 |
2019-08-21 |
Allergan, Inc. |
Ester prodrugs of gamma-lactams and their use
|
US10689423B2
(en)
|
2015-01-13 |
2020-06-23 |
City Of Hope |
CTLA4-binding protein peptide-linker masks
|
DK3261640T3
(da)
|
2015-02-25 |
2022-07-11 |
Univ California |
5ht-agonister til behandling af epilepsilidelser
|
HUE060104T2
(hu)
|
2015-02-27 |
2023-01-28 |
Verseon Int Corporation |
Szubsztituált pirazol vegyületek mint szerinproteázinhibitorok
|
EP3262040A4
(en)
|
2015-02-27 |
2018-09-12 |
The Regents of The University of California |
Small molecules that enable cartilage rejuvanation
|
US10246424B2
(en)
|
2015-04-10 |
2019-04-02 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use thereof
|
ES2856880T3
(es)
|
2015-04-15 |
2021-09-28 |
Araxes Pharma Llc |
Inhibidores tricíclicos condensados de KRAS y métodos de uso de los mismos
|
EP3283482B1
(en)
|
2015-04-17 |
2022-04-06 |
Ludwig Institute for Cancer Research Ltd |
Plk4 inhibitors
|
US20180282310A1
(en)
|
2015-06-10 |
2018-10-04 |
Biogen Ma Inc. |
Forms and compositions of biaryl inhibitors of bruton's tyrosine kinase
|
US10144724B2
(en)
|
2015-07-22 |
2018-12-04 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use thereof
|
CN105132566A
(zh)
*
|
2015-09-21 |
2015-12-09 |
上海中优生物高科技有限责任公司 |
毒素堆积型肥胖基因个体化干预饮品的制备方法及其系统
|
US10730867B2
(en)
|
2015-09-28 |
2020-08-04 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
EP3356359B1
(en)
|
2015-09-28 |
2021-10-20 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
US10647703B2
(en)
|
2015-09-28 |
2020-05-12 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
EP3356349A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
US10689356B2
(en)
|
2015-09-28 |
2020-06-23 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
US10875842B2
(en)
|
2015-09-28 |
2020-12-29 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
US10858343B2
(en)
|
2015-09-28 |
2020-12-08 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
AU2016335563B2
(en)
|
2015-10-08 |
2022-10-27 |
Neurona Therapeutics Inc. |
Neural precursor cell populations and uses thereof
|
EP3364977A4
(en)
|
2015-10-19 |
2019-09-04 |
Araxes Pharma LLC |
PROCESS FOR SCREENING INHIBITORS OF RAS
|
CA3002924A1
(en)
|
2015-10-23 |
2017-04-27 |
Erx Pharmaceuticals Inc. |
Analogs of celastrol
|
MX2018004977A
(es)
|
2015-10-23 |
2018-07-06 |
Sunesis Pharmaceuticals Inc |
Inhibidores heterociclicos de la proteina cinasa 1 dependiente de 3-fosfoinositido (pdk1) para usarse en el tratamiento del cancer.
|
US10414757B2
(en)
|
2015-11-16 |
2019-09-17 |
Araxes Pharma Llc |
2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof
|
US9988357B2
(en)
|
2015-12-09 |
2018-06-05 |
Araxes Pharma Llc |
Methods for preparation of quinazoline derivatives
|
KR20180102590A
(ko)
|
2015-12-24 |
2018-09-17 |
더 리젠츠 오브 더 유니버시티 오브 캘리포니아 |
Cftr 조절제 및 이의 사용방법
|
KR20180101416A
(ko)
|
2015-12-24 |
2018-09-12 |
더 리젠츠 오브 더 유니버시티 오브 캘리포니아 |
Cftr 조절제 및 이의 이용 방법
|
JP7019578B2
(ja)
|
2015-12-30 |
2022-02-15 |
セルジーン コーポレイション |
Tリンパ球の産生方法及びそれにより産生されるtリンパ球
|
US10822312B2
(en)
|
2016-03-30 |
2020-11-03 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use
|
PT3458448T
(pt)
|
2016-04-25 |
2021-09-10 |
Forma Therapeutics Inc |
Inibidores fasn para uso no tratamento de esteato-hepatite não-alcoólica
|
WO2017190107A1
(en)
|
2016-04-29 |
2017-11-02 |
Board Of Regents, The University Of Texas System |
Sigma receptor binders
|
EP3578562B1
(en)
|
2016-05-12 |
2021-06-23 |
Anacor Pharmaceuticals, Inc |
L-valinate amide benzoxaborole derivatives for the treatment of parasitic diseases
|
US10646488B2
(en)
|
2016-07-13 |
2020-05-12 |
Araxes Pharma Llc |
Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
|
BR112019001158A2
(pt)
|
2016-07-21 |
2019-04-30 |
Biogen Ma, Inc. |
formas de succinato e composições de inibidores da tirosina quinase de bruton
|
US11584780B2
(en)
|
2016-07-26 |
2023-02-21 |
Biomarin Pharmaceutical Inc. |
Adeno-associated virus capsid proteins
|
US11542261B2
(en)
|
2016-08-17 |
2023-01-03 |
Children's Hospital Medical Center |
Substituted Imidazo[1,2-a]-pyridines as IRAK 1/4 and FLT3 inhibitors
|
US11254667B2
(en)
|
2016-08-17 |
2022-02-22 |
Children's Hospital Medical Center |
Substituted imidazo[1,2-A]pyridines as IRAK 1/4 and flt3 inhibitors
|
FI3509624T3
(fi)
|
2016-09-12 |
2023-10-18 |
Amryt Pharmaceuticals Inc |
Menetelmiä neutraloivien anti-leptiini -vasta-aineiden havaitsemiseksi
|
EP3519402A1
(en)
|
2016-09-29 |
2019-08-07 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
US10377743B2
(en)
|
2016-10-07 |
2019-08-13 |
Araxes Pharma Llc |
Inhibitors of RAS and methods of use thereof
|
EP3528851B1
(en)
|
2016-10-20 |
2022-04-27 |
Celgene Corporation |
Cereblon-based heterodimerizable chimeric antigen receptors
|
JP7191828B2
(ja)
|
2016-12-15 |
2022-12-19 |
ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア |
がん治療のための組成物および方法
|
EP3573970A1
(en)
|
2017-01-26 |
2019-12-04 |
Araxes Pharma LLC |
1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
|
EP3573967A1
(en)
|
2017-01-26 |
2019-12-04 |
Araxes Pharma LLC |
Fused hetero-hetero bicyclic compounds and methods of use thereof
|
EP3573964A1
(en)
|
2017-01-26 |
2019-12-04 |
Araxes Pharma LLC |
Benzothiophene and benzothiazole compounds and methods of use thereof
|
EP3573971A1
(en)
|
2017-01-26 |
2019-12-04 |
Araxes Pharma LLC |
1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
|
WO2018140512A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
|
CA3063440A1
(en)
|
2017-05-25 |
2018-11-29 |
Araxes Pharma Llc |
Covalent inhibitors of kras
|
WO2018218069A1
(en)
|
2017-05-25 |
2018-11-29 |
Araxes Pharma Llc |
Quinazoline derivatives as modulators of mutant kras, hras or nras
|
JP2020521741A
(ja)
|
2017-05-25 |
2020-07-27 |
アラクセス ファーマ エルエルシー |
がんの処置のための化合物およびその使用の方法
|
CN107385020A
(zh)
*
|
2017-06-23 |
2017-11-24 |
西安医学院 |
瘦素在人重组fgf21蛋白活性检测中的应用
|
WO2019070917A1
(en)
|
2017-10-03 |
2019-04-11 |
The Schepens Eye Research Institute, Inc. |
COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE DEGENERATION OF RETINAL PIGMENT EPITHELIUM AND METHODS USING SAME
|
JP2020536920A
(ja)
|
2017-10-10 |
2020-12-17 |
サイロス ファーマシューティカルズ, インコーポレイテッド |
ピロロトリアジン化合物およびtamキナーゼを阻害する方法
|
US11311542B2
(en)
|
2018-01-16 |
2022-04-26 |
Syros Pharmaceuticals, Inc. |
Inhibitors of cyclin dependent kinase 7 (CDK7)
|
EP3765459A1
(en)
|
2018-03-13 |
2021-01-20 |
Shire Human Genetic Therapies, Inc. |
Substituted imidazopyridines as inhibitors of plasma kallikrein and uses thereof
|
BR112020022722A8
(pt)
|
2018-05-09 |
2022-01-18 |
Biomarin Pharm Inc |
Genoma e seu uso, vetor, partícula, molécula de ácido nucleico isolada, ácido nucleico, composição, tratamento, método
|
TW202005978A
(zh)
|
2018-05-14 |
2020-02-01 |
美商拜奧馬林製藥公司 |
新穎肝靶向腺相關病毒載體
|
EP4031547A1
(en)
|
2019-09-18 |
2022-07-27 |
Takeda Pharmaceutical Company Limited |
Plasma kallikrein inhibitors and uses thereof
|
JP2022549601A
(ja)
|
2019-09-18 |
2022-11-28 |
武田薬品工業株式会社 |
ヘテロアリール血漿カリクレインインヒビター
|
WO2021211938A1
(en)
|
2020-04-17 |
2021-10-21 |
Shire Human Genetic Therapies, Inc. |
Solid forms of inhibitors of plasma kallikrein
|
JP2023522331A
(ja)
|
2020-04-17 |
2023-05-30 |
武田薬品工業株式会社 |
血漿カリクレインの阻害剤の形態及び組成物
|
CN117355523A
(zh)
|
2021-03-17 |
2024-01-05 |
武田药品工业株式会社 |
血浆激肽释放酶的多环抑制剂
|
EP4308228A1
(en)
|
2021-03-17 |
2024-01-24 |
Takeda Pharmaceutical Company Limited |
Plasma kallikrein inhibitors
|
CA3208243A1
(en)
|
2021-03-17 |
2022-09-22 |
Nikolaos PAPAIOANNOU |
Heteroaryl inhibitors of plasma kallikrein
|
EP4308229A1
(en)
|
2021-03-17 |
2024-01-24 |
Takeda Pharmaceutical Company Limited |
Inhibitors of plasma kallikrein
|
JP2024510502A
(ja)
|
2021-03-17 |
2024-03-07 |
武田薬品工業株式会社 |
血漿カリクレインのイミダゾピリジニル阻害剤
|
CA3223636A1
(en)
|
2021-08-06 |
2023-02-09 |
Christopher Walton CARROLL |
Compositions and methods for selective degradation of engineered proteins
|
WO2024040241A1
(en)
|
2022-08-19 |
2024-02-22 |
Viracta Therapeutics, Inc. |
Pharmaceutical formulations, processes for preparation, and methods of use
|
WO2024059186A1
(en)
|
2022-09-15 |
2024-03-21 |
Takeda Pharmaceutical Company Limited |
N-((isoquinolin-6-yl)methyl)-1h-pyrazole-4-carboxamid derivatives as plasma kallikrein inhibitors for the treatment of hereditary angioedema
|